Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 4.22%791M | -83.97%100M | 22.85%699M | 18.07%2.65B | 64.07%694M | -12.46%759M | 25.30%624M | 25.61%569M | 145.45%2.24B | 1,107.14%423M |
| Net income from continuing operations | 978.26%248M | 4.76%154M | 167.11%601M | -45.65%568M | -43.65%173M | -80.51%23M | 234.09%147M | -60.94%225M | 3.57%1.05B | --307M |
| Operating gains losses | 168.49%50M | 94.97%-8M | -734.15%-260M | 97.75%-17M | 448.00%174M | -46.00%-73M | -1,545.45%-159M | 106.15%41M | -879.38%-756M | ---50M |
| Depreciation and amortization | 8.36%324M | 8.53%318M | 12.24%321M | 9.91%1.17B | 7.89%287M | 9.93%299M | 10.98%293M | 10.85%286M | 10.53%1.06B | --266M |
| Asset impairment expenditure | --0 | ---- | ---- | --214M | --4M | --210M | ---- | ---- | --0 | --0 |
| Deferred tax | 94.12%-1M | -241.67%-17M | 621.05%137M | -296.91%-191M | -612.50%-205M | 52.78%-17M | 119.67%12M | -87.66%19M | -36.18%97M | --40M |
| Other non cashItems | -2.17%45M | -84.06%51M | -210.00%-66M | -48.88%455M | 172.50%29M | -86.71%46M | 27.49%320M | -81.98%60M | 177.87%890M | 97.95%-40M |
| Change In working capital | -53.87%125M | -4,400.00%-473M | 45.16%-34M | 575.79%452M | 332.00%232M | 24.88%271M | 200.00%11M | 69.15%-62M | 59.40%-95M | 73.89%-100M |
| -Change in receivables | -70.71%29M | -3,750.00%-219M | -180.00%-40M | -123.58%-154M | -296.15%-309M | 3,200.00%99M | -95.68%6M | -91.51%50M | 202.67%653M | ---78M |
| -Change in inventory | -200.00%-31M | -85.71%-78M | -54.55%25M | 222.58%38M | -115.00%-6M | 875.00%31M | 58.00%-42M | 66.67%55M | 85.51%-31M | --40M |
| -Change in payables and accrued expense | 15.22%53M | -150.71%-71M | 39.60%-151M | 199.63%536M | 19,900.00%600M | -66.42%46M | 976.92%140M | 63.82%-250M | -227.19%-538M | --3M |
| -Change in other current liabilities | -22.11%74M | -12.90%-105M | 59.04%132M | 117.88%32M | 18.46%-53M | 17.28%95M | -47.62%-93M | 162.88%83M | -192.75%-179M | ---65M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 4.22%791M | -83.97%100M | 22.85%699M | 18.07%2.65B | 64.07%694M | -12.46%759M | 25.30%624M | 25.61%569M | 145.45%2.24B | 1,107.14%423M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 3.20%-846M | -610.05%-964M | -17.22%-708M | 23.96%-2.22B | -6.54%-929M | -24.50%-874M | 126.88%189M | 5.63%-604M | -13.55%-2.92B | -872M |
| Net PPE purchase and sale | 3.42%-846M | -33.51%-996M | -20.47%-724M | -7.29%-3.15B | -6.18%-928M | -23.03%-876M | -4.48%-746M | 5.65%-601M | -13.14%-2.94B | ---874M |
| Net business purchase and sale | --0 | ---- | ---- | --927M | --0 | --0 | ---- | ---- | --0 | --0 |
| Net other investing changes | --0 | 300.00%32M | 633.33%16M | -70.00%6M | -150.00%-1M | -80.00%2M | -27.27%8M | 0.00%-3M | -25.93%20M | --2M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 3.20%-846M | -610.05%-964M | -17.22%-708M | 23.96%-2.22B | -6.54%-929M | -24.50%-874M | 126.88%189M | 5.63%-604M | -13.55%-2.92B | 1.36%-872M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 6,300.00%64M | 206.20%754M | 142.71%123M | -187.11%-818M | -76.84%179M | 100.43%1M | -387.45%-710M | -288.24%-288M | -39.61%939M | 773M |
| Net issuance payments of debt | 3,228.57%219M | 257.69%902M | 254.76%260M | -145.70%-494M | -51.06%253M | 92.63%-7M | -255.01%-572M | -157.93%-168M | -40.60%1.08B | --517M |
| Net common stock issuance | -93.33%10M | -47.37%10M | -35.48%20M | -33.02%284M | -79.05%84M | 3,650.00%150M | 58.33%19M | 342.86%31M | 53.07%424M | --401M |
| Cash dividends paid | -9.33%-164M | -3.95%-158M | -3.97%-157M | -10.29%-611M | -6.76%-158M | -7.91%-150M | -14.29%-152M | -12.69%-151M | -3.55%-554M | ---148M |
| Net other financing activities | ---- | ---- | ---- | 125.00%3M | --0 | 300.00%8M | ---- | ---- | -71.43%-12M | --3M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 6,300.00%64M | 206.20%754M | 142.71%123M | -187.11%-818M | -76.84%179M | 100.43%1M | -387.45%-710M | -288.24%-288M | -39.61%939M | 8.72%773M |
| Net cash flow | ||||||||||
| Beginning cash position | -42.78%218M | 21.38%335M | -62.41%221M | 77.11%588M | -3.30%264M | 13.73%381M | -8.61%276M | 77.11%588M | -20.38%332M | -50.27%273M |
| Current changes in cash | 107.89%9M | -206.80%-110M | 135.29%114M | -248.29%-390M | -117.28%-56M | -65.22%-114M | 145.24%103M | -850.00%-323M | 360.40%263M | 250.70%324M |
| Effect of exchange rate changes | 166.67%2M | -450.00%-7M | --0 | 428.57%23M | 244.44%13M | -142.86%-3M | 122.22%2M | 175.00%11M | -143.75%-7M | -350.00%-9M |
| End cash Position | -13.26%229M | -42.78%218M | 21.38%335M | -62.41%221M | -62.41%221M | -3.30%264M | 13.73%381M | -8.61%276M | 77.11%588M | 77.11%588M |
| Free cash from | 52.99%-55M | -634.43%-896M | 21.88%-25M | 27.44%-505M | 48.12%-234M | -175.48%-117M | 43.52%-122M | 82.61%-32M | 58.65%-696M | 82.90%-451M |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.